12:00 AM
 | 
Aug 10, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

VMAT2: Phase I start

This month, Neurocrine will begin a single ascending-dose, Canadian Phase I trial to evaluate NBI-98854.

Read the full 60 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >